Complete 2026 comparison chart. A side-by-side comparison of every major FDA-approved GLP-1 medication based on published clinical trial data and FDA labels. This is informational only — consult your healthcare provider before making any medication decisions.
Every major FDA-approved GLP-1 medication at a glance.
| Medication | Ozempic® | Wegovy® Injection | Wegovy® Pill | Wegovy® HD | Mounjaro® | Zepbound® | Rybelsus® | Saxenda® |
|---|---|---|---|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide 2.4mg | Oral semaglutide 25mg | Semaglutide 7.2mg | Tirzepatide | Tirzepatide | Oral semaglutide | Liraglutide |
| Drug class | GLP-1 RA | GLP-1 RA | GLP-1 RA | GLP-1 RA | Dual GLP-1/GIP | Dual GLP-1/GIP | GLP-1 RA | GLP-1 RA |
| FDA indication | Type 2 diabetes | Weight management | Weight management | Weight management | Type 2 diabetes | Weight management | Type 2 diabetes | Weight management |
| Administration | Weekly injection | Weekly injection | Daily tablet | Weekly injection | Weekly injection | Weekly injection | Daily tablet | Daily injection |
| Frequency | Once weekly | Once weekly | Once daily | Once weekly | Once weekly | Once weekly | Once daily | Once daily |
| FDA approval | 2017 | 2021 | Dec 2025 | Mar 2026 | 2022 | 2023 | 2019 | 2014 |
| Key trial | SUSTAIN | STEP 1 | OASIS 4 | Higher dose data | SURPASS | SURMOUNT-1 | PIONEER | SCALE |
| Avg weight loss (trial) | Secondary endpoint | ~14.9% | ~16.6% | TBD | Varies by dose | ~20.9% | Modest | ~8% |
| Manufacturer | Novo Nordisk | Novo Nordisk | Novo Nordisk | Novo Nordisk | Eli Lilly | Eli Lilly | Novo Nordisk | Novo Nordisk |
| Approx list price | ~$935/mo | ~$1,349/mo | Starting ~$149/mo | TBD | ~$1,023/mo | ~$1,059/mo | ~$935/mo | ~$1,349/mo |
Scroll sideways to see all eight medications. Pricing reflects approximate list prices and does not account for insurance, savings programs, or pharmacy discounts.
The chart splits two ways: by which hormones the molecule targets, and by how it is taken.
Dive deeper into specific medication matchups.
This table presents published data from FDA labels and clinical trials. Clinical trials for each medication had different designs, patient populations, inclusion criteria, and durations — results across different trials cannot be directly compared. Weight loss percentages are trial averages; individual results vary significantly. Pricing reflects approximate list prices and does not account for insurance, savings programs, or pharmacy discounts. Only your healthcare provider can determine which medication is appropriate for you.
No matter which GLP-1 you're on, Dose AI tracks your doses, symptoms, weight, and nutrition in one place.
Clinical trials have shown varying levels of weight loss across different GLP-1 medications. Tirzepatide (Zepbound) showed approximately 20.9% average weight loss in SURMOUNT-1, while semaglutide (Wegovy injection) showed approximately 14.9% in STEP 1. However, these were separate trials with different populations and cannot be directly compared. Individual responses vary significantly, and your healthcare provider can help determine which option is appropriate for you.
As of early 2026, the most recent GLP-1 approvals include the Wegovy pill (oral semaglutide 25mg, approved December 2025) and Wegovy HD (semaglutide 7.2mg injection, approved March 2026). Eli Lilly's orforglipron, an oral non-peptide GLP-1, is currently under FDA review.
No. While most GLP-1 medications are injections, oral options exist. Rybelsus (oral semaglutide) is approved for type 2 diabetes, and the Wegovy pill (oral semaglutide 25mg) is approved for weight management. Eli Lilly's orforglipron, another oral option, is under FDA review. The trend is toward more oral options becoming available.
The Wegovy pill launched with a starting price around $149/month through manufacturer savings offers, making it the most affordable branded option at list price. However, actual out-of-pocket costs depend on insurance coverage, pharmacy, and available savings programs. Some medications may be better covered by certain insurance plans.
Yes. Dose AI tracks any GLP-1 medication regardless of brand or formulation. Whether you take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1, the app helps you log doses, track symptoms, monitor weight changes, and manage your nutrition.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.
